MedPage Today (8/17, George) reports research indicates that patients with Parkinson’s disease “using pimavanserin (Nuplazid), a novel antipsychotic used to help manage Parkinson’s hallucinations and delusions, had an increased risk of 30-day hospitalization and higher mortality for up to a year.” The study compared “2,186 people who were prescribed pimavanserin and 18,212 who were not.” The findings were published online in the journal Neurology.
Related Links:
— MedPage Today (requires login and subscription)